Bluebird bio Can Restart Halted Clinical Trials
The Food and Drug Administration (FDA) has told bluebird bio (NASDAQ: BLUE) it can resume trials of its experimental gene therapy, LentiGlobin, after it determined the therapy wasn't responsible for a rare case of cancer diagnosed in a trial participant earlier this year.
IMAGE SOURCE: GETTY IMAGES.
Using a lentiviral vector, LentiGlobin inserts a modified gene in patients that allows them to produce enough adult hemoglobin to potentially eliminate or significantly reduce the need for transfusions.
Source Fool.com
